RECOMBINANT POXVIRUS BASED VACCINE AGAINST SARS-CoV-2 VIRUS
AssigneeTonix Pharmaceuticals Holding Corp
InventorsSeth Lederman, Scott J. Goebel, David Evans, Ryan Noyce
Life of this patent
Estimating the term…
Abstract
The invention relates in various aspects to a recombinant poxvirus comprising a nucleic acid encoding a SARS-CoV-2 virus protein, methods for producing such viruses and the use of such viruses. The recombinant poxviruses are well suited, among others, as protective virus vaccines against SARS-CoV-2 virus.
Claims50
A recombinant poxvirus comprising a nucleic acid encoding a SARS-CoV-2 virus protein, wherein the SARS-CoV-2 protein is selected from the group consisting of the spike protein (S), the membrane protein (M) and the nucleocapsid protein (N), or combinations of two or more of said proteins.
6-7. (canceled)
(canceled)
(canceled)
18-19. (canceled)
(canceled)
26-29. (canceled)
33-38. (canceled)
40-43. (canceled)
(canceled)
50-55. (canceled)
60-64. (canceled)
67-82. (canceled)
84-85. (canceled)
(canceled)
Dependencies are inferred from the claim text.